XML 25 R6.htm IDEA: XBRL DOCUMENT v3.6.0.2
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Cash flows from operating activities      
Net income (loss) $ 97,678 $ (30,141) $ 1,387
Adjustments to reconcile net income (loss) to net cash used in operating activities:      
Deferred tax benefit (61,396) 0 0
Depreciation and amortization 979 2,019 1,865
Amortization of debt issuance costs 1,152 987 100
Debt prepayment penalty 228 0 0
Impairment of property, equipment, inventory and intangibles 520 2,087 355
Provision for bad debt expense and note receivable 13 633 500
Interest costs added to principal balance of notes payable 0 923 1,124
Consulting expense financed through note payable 0 0 1,600
Share-based compensation expense 2,868 7,204 4,712
Clawback of equity awards 0 (325) 0
Earnings from equity method investments (45,584) (8,921) (42,712)
Gain on sale of equity method investment (2,078) 0 0
Impairment of cost method investment 1,760 0 0
Gain on settlement of note payable, licensed technology, and sales-type lease (1,910) 0 0
Other non-cash items, net 35 285 39
Changes in operating assets and liabilities, net of effects of acquired businesses:      
Receivables (301) 8,361 (3,651)
Related party receivables (16) (479) (809)
Prepaid expenses and other assets 1,195 (107) (1,877)
Costs incurred on uncompleted contracts 29,623 6,492 (56,606)
Other long-term assets 961 205 (47)
Accounts payable (4,254) (1,340) 2,328
Accrued payroll and related liabilities (2,887) (102) 686
Other current liabilities (3,105) (812) (672)
Billings on uncompleted contracts (32,272) (15,186) 55,621
Advance deposit, related party (2,980) (3,544) (2,135)
Other long-term liabilities (2,175) 595 144
Legal settlements and accruals (4,211) (3,722) (4,622)
Distributions from equity method investees, return on investment 7,900 5,019 2,509
Net cash used in operating activities (18,257) (29,869) (40,161)
Cash flows from investing activities      
Distributions from equity method investees in excess of cumulative earnings 38,250 8,651 43,584
Purchase of investment securities 0 0 (105)
Maturity of investment securities 0 0 210
Maturity of investment securities, restricted 336 0 403
Acquisition of property and equipment (289) (507) (1,563)
Proceeds from sale of property and equipment 52 942 26
Advance on note receivable 0 (500) (500)
Acquisition of business 0 (2,124) 0
Purchase of cost method investment 0 0 (2,776)
Purchase of and contributions to equity method investee (223) (2,128) (6,631)
Proceeds from sale of equity method investment 1,773 0 0
Net cash provided by investing activities 39,899 4,334 32,648
Cash flows from financing activities      
Short-term borrowings 0 13,539 0
Repayments on short-term borrowings (13,250) (1,750) 0
Repayments on notes payable, related party (1,246) (1,484) (238)
Loan costs and amendment fees (751) 0 (70)
Debt prepayment penalty (228) 0 0
Proceeds received upon exercise of stock options 0 0 243
Repurchase of shares to satisfy tax withholdings (196) (276) (1,500)
Net cash (used in) provided by financing activities (15,671) 10,029 (1,565)
Increase (Decrease) in Cash and Cash Equivalents and Restricted Cash 5,971 (15,506) (9,078)
Cash and Cash Equivalents and Restricted Cash, beginning of year 20,973 36,479 45,557
Cash and Cash Equivalents and Restricted Cash, end of year 26,944 20,973 36,479
Supplemental disclosure of cash flow information:      
Cash paid for interest 3,647 6,274 5,201
Cash paid for income taxes 541 29 566
Supplemental disclosure of non-cash investing and financing activities:      
Acquisition of technology license through long-term payable 0 0 1,525
Acquisition of equity method investment through note payable 0 0 13,301
Settlement of RCM6 note payable 13,234 0 0
Non-cash reduction of equity method investment 11,156 0 0
Stock award reclassification (liability to equity) 899 0 501
Issuance of common stock to settle liabilities $ 0 $ 0 $ 127